Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2007-07-31 Major Shareholding Noti…
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G HOLDINGS REPORT
Major Shareholding Notification
2007-07-31 English
Capital/Financing Update 2007
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) under a Registration Statement No. 333-144495. It details the offering and resale of common stock and warrants by selling shareholders, including information about the company, risk factors, use of proceeds, and plan of distribution. This type of document is a capital markets filing related to fundraising and securities offering, not a financial report, earnings release, or management discussion. It is not an annual or quarterly report, nor an audit or governance document. The presence of terms like 'prospectus', 'shares', 'selling shareholders', 'plan of distribution', and 'use of proceeds' clearly indicate this is a Capital/Financing Update filing. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and detail support a high confidence score.
2007-07-31 English
Regulatory Filings 2007
Regulatory Filings
2007-07-31 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes an announcement about a clinical trial update and references a press release attached as an exhibit. There are no financial statements or detailed financial data presented. The document is short (2683 characters) and primarily serves as a regulatory announcement of an event rather than a detailed financial or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2007-07-30 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes an announcement about a clinical hold placed by the FDA on a development program, and it includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The document is a regulatory announcement of an event rather than a financial report or earnings release. Given the nature of the filing and the absence of financial data, this fits best under Regulatory Filings (RNS). The document length is short (2506 characters), and it is not a report publication announcement or a certification. Therefore, the classification is RNS with high confidence.
2007-07-25 English
PRIMARY DOCUMENT
Director's Dealing
2007-07-12 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.